Isis Pharmaceuticals Inc. and Genzyme Corp.'s statin add-on mipomersen met its Phase III endpoint in the rare disorder homozygous familial hypercholesterolemia (hoFH), but six trial dropouts from 34 patients bothered Wall Street. One was caused by hiked liver enzymes, which has been a problem in other studies, too. (BioWorld Today) Read More
